10,284 Shares in Charles River Laboratories International, Inc. $CRL Purchased by Oliver Luxxe Assets LLC

Key Points

• Oliver Luxxe Assets LLC opened a new position in Charles River Laboratories, buying 10,284 shares in Q4 valued at about $2.05 million, and institutional investors now own roughly 98.91% of the company.
• Analysts are mixed but broadly positive: the stock has a consensus rating of "Moderate Buy" with an average target of $206.15, while recent notes range from UBS's $175 neutral to Citigroup's $265 buy.
• Charles River beat quarterly estimates with $2.39 EPS and $994.23 million revenue, provided FY2026 EPS guidance of 10.700–11.200, but still shows a negative net margin (-3.59%).

Oliver Luxxe Assets LLC acquired a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 10,284 shares of the medical research company's stock, valued at approximately $2,051,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Hantz Financial Services Inc. lifted its position in shares of Charles River Laboratories International by 11.2% in the third quarter. Hantz Financial Services Inc. now owns 793 shares of the medical research company's stock worth $124,000 after purchasing an additional 80 shares in the last quarter. Advisory Services Network LLC boosted its holdings in shares of Charles River Laboratories International by 2.6% during the third quarter. Advisory Services Network LLC now owns 3,226 shares of the medical research company's stock worth $505,000 after purchasing an additional 83 shares during the period. Rothschild Investment LLC grew its position in Charles River Laboratories International by 82.4% during the third quarter. Rothschild Investment LLC now owns 186 shares of the medical research company's stock valued at $29,000 after purchasing an additional 84 shares in the last quarter. Patriot Financial Group Insurance Agency LLC increased its stake in Charles River Laboratories International by 4.2% in the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 2,120 shares of the medical research company's stock valued at $332,000 after buying an additional 85 shares during the period. Finally, Resona Asset Management Co. Ltd. increased its stake in Charles River Laboratories International by 17.5% in the 3rd quarter. Resona Asset Management Co. Ltd. now owns 584 shares of the medical research company's stock valued at $86,000 after buying an additional 87 shares during the period. Hedge funds and other institutional investors own 98.91% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on CRL shares. UBS Group lifted their target price on shares of Charles River Laboratories International from $170.00 to $175.00 and gave the company a "neutral" rating in a research note on Wednesday, February 25th. Wall Street Zen downgraded shares of Charles River Laboratories International from a "buy" rating to a "hold" rating in a research note on Saturday, February 21st. Citigroup increased their price objective on Charles River Laboratories International from $200.00 to $265.00 and gave the stock a "buy" rating in a report on Friday, January 16th. Weiss Ratings reissued a "sell (d)" rating on shares of Charles River Laboratories International in a research report on Wednesday, January 21st. Finally, Robert W. Baird set a $193.00 target price on Charles River Laboratories International in a research note on Thursday, February 19th. Ten research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $206.15.

Charles River Laboratories International Stock Performance

CRL stock opened at $153.52 on Friday. The company has a quick ratio of 1.02, a current ratio of 1.29 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $7.56 billion, a price-to-earnings ratio of -51.86, a P/E/G ratio of 2.63 and a beta of 1.64. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $228.88. The firm has a 50 day moving average of $185.42 and a two-hundred day moving average of $180.69.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings results on Wednesday, February 18th. The medical research company reported $2.39 earnings per share for the quarter, beating analysts' consensus estimates of $2.33 by $0.06. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. The business had revenue of $994.23 million for the quarter, compared to the consensus estimate of $986.98 million. During the same quarter last year, the firm earned $2.66 EPS. Charles River Laboratories International's revenue for the quarter was down .8% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. As a group, equities analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company's core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.